Clinical trials: Breast
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone is a drug which blocks some effects of chemicals called beta-endorphins that are made in the body. Beta-endorphins can be made in response to stress, injury, and also pleasurable activities.
- Conditions
- Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma
- Trial name
- NCT02137252
- Testing
- Naltrexone, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Bone Metastases
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
- Trial name
- NCT00321464
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 2,049 people
- Sponsor
- Amgen
Cognitive Side Effects of Cancer Therapy, Depression
Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness…
- Conditions
- Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- IMPACT (NCT02415387)
- Testing
- typhoid vaccine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ketamine, Lactation
The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women
Quantification of Ketamine in Breast Milk at 3 hour Intervals up to 30 hours-- obtained from lactating women who receive 2 different Intramuscular injections of ketamine on two separate days at least 5 days apart.
- Trial name
- KRF-LAC (NCT04285684)
- Testing
- ketamine in lactation
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- The Ketamine Research Foundation
Invasive Breast Carcinoma, Recurrent Breast Carcinoma
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast…
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT00601900
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole
- Where
- 522 sites in United States, Puerto Rico
- Volunteers
- 394 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in…
- Trial name
- PUFFIN (NCT02896855)
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 15 sites in China
- Volunteers
- 243 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Lymphedema
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy (CDT) when compared to CDT treatment alone.
- Trial name
- NCT01351376
- Testing
- Low Level Laser Therapy, Low Level Laser
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
Breast Cancer
A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.
CDK4/6 inhibitors are approved medicines indicated for the treatment of a kind of advanced/metastatic breast cancer, called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease.
- Trial name
- NCT05770713
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Pfizer
Hormone Receptor Positive Breast Cancer
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2…
- Trial name
- BOLERO-4 (NCT01698918)
- Testing
- Everolimus, Letrozole, Exemestane
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087178
- Testing
- cyclophosphamide, adriamycin, epirubicin
- Where
- 606 sites in United States, Canada and 1 more
- Volunteers
- 2,722 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an…
- Trial name
- NCT02383576
- Testing
- No Intervention
- Where
- 32 sites in Brazil, France and 4 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Decision Support Workshop for Breast Reconstruction
The purpose of this study is to determine the effectiveness of a pre-consultation decision support workshop for breast reconstruction after breast cancer, in facilitating the decision-making process, compared to routine…
- Trial name
- DSW (NCT01857882)
- Testing
- Decision Support Workshop
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy
The main purpose of the investigation is to determine if curcumin reduces NF-kB DNA binding and ultimately its downstream mediator IL-6 in patients receiving XRT for their breast cancer after having completed chemotherapy.
- Trial name
- NCT01740323
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Andrew H Miller
Breast Cancer
Melatonin Versus Placebo in Breast Cancer
The purpose of this research study is to determine whether melatonin taken every night can affect blood levels of estrogen or IGF (insulin-growth factor levels).
- Trial name
- NCT01805089
- Testing
- Melatonin 3 mg
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
This study will assess the efficacy and safety of intravenous (IV) trastuzumab (Herceptin) and IV docetaxel (Taxotere), with or without oral capecitabine (Xeloda), in women with previously untreated HER2-positive advanced and/or…
- Trial name
- NCT02748213
- Testing
- Xeloda, Taxotere, Herceptin
- Where
- 51 sites in Australia, Brazil and 13 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Invasive Breast Cancer
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
- Trial name
- NCT03564782
- Testing
- PVSRIPO
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Istari Oncology, Inc.
Breast Cancer
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00379197
- Testing
- naltrexone, PET scan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Invasive Breast Cancer
Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"
This is a prospective examination of tumor material of breast cancer patients randomized into the FinHer-trial (= (= Comparison of vinorelbine and docetaxel and trastuzumab as adjuvant treatments of breast cancer patients wirh a…
- Trial name
- NCT02244580
- Testing
- MammaTyper™
- Volunteers
- 1,010 people
- Sponsor
- BioNTech Diagnostics GmbH
Triple Negative Breast Cancer
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC)…
- Trial name
- OPALESCENCE (NCT04758780)
- Testing
- 89Zr-TLX250
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.